{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:33:27Z","timestamp":1785234807800,"version":"3.55.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The aim of this retrospective multicenter study was to clarify the antifibrotic effect and long\u2010term outcome of sodium glucose cotransporter 2 inhibitors (SGLT2\u2010Is) in patients with nonalcoholic fatty liver disease (NAFLD) complicated by type 2 diabetes mellitus (T2DM). Of the 1262 consecutive patients with T2DM who recently received SGLT2\u2010Is, 202 patients with NAFLD had been receiving SGLT2\u2010Is for more than 48\u2009weeks and were subjected to this analysis. Furthermore, 109 patients who had been on SGLT2\u2010I therapy for more than 3\u2009years at the time of analysis were assessed for the long\u2010term effects of SGLT2\u2010Is. Significant decreases in body weight, liver transaminases, plasma glucose, hemoglobin A1c, and Fibrosis\u20104 (FIB\u20104) index were found at week 48. Overall, the median value of FIB\u20104 index decreased from 1.42 at baseline to 1.25 at week 48 (<jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0&lt;\u20090.001). In the low\u2010risk group (FIB\u20104 index\u2009&lt;\u20091.3), there was no significant change in the FIB\u20104 index. In the intermediate\u2010risk (\u22651.3\u00a0and\u2009&lt;2.67) and high\u2010risk (\u22652.67) groups, the median levels significantly decreased from 1.77 and 3.33 at baseline to 1.58 and 2.75 at week 48, respectively (<jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0&lt;\u20090.001 for both). Improvements in body weight, glucose control, liver transaminases, and FIB\u20104 index were found at 3\u2009years of SGLT2\u2010I treatment. In the intermediate\u2010risk and high\u2010risk groups (\u22651.3\u00a0FIB\u20104 index), the FIB\u20104 index maintained a significant reduction from baseline throughout the 3\u2009years of treatment. <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> This study showed that SGLT2\u2010Is offered a favorable effect on improvement in FIB\u20104 index as a surrogate marker of liver fibrosis in patient with NAFLD complicated by T2DM, especially those with intermediate and high risks of advanced fibrosis, and this antifibrotic effect is sustained for the long term.<\/jats:p>","DOI":"10.1002\/hep4.2069","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T07:11:21Z","timestamp":1661843481000},"page":"3073-3082","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":52,"title":["Antifibrotic effect and long\u2010term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus"],"prefix":"10.1097","volume":"6","author":[{"given":"Taeang","family":"Arai","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tsubota","sequence":"additional","affiliation":[{"name":"Core Research Facilities for Basic Science, Research Center for Medical Sciences,The Jikei University School of Medicine,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Mikami","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine,Kikkoman General Hospital,Miyazaki Noda,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1719-1352","authenticated-orcid":false,"given":"Uojima","family":"Haruki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Internal Medicine,Kitasato University School of Medicine,Sagamihara,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Yoshikata","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ono","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadamichi","family":"Kawano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology,Nippon Medical School Chiba Hokusoh Hospital,Chiba,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohide","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Okubo","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology,Nippon Medical School Chiba Hokusoh Hospital,Chiba,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korenobu","family":"Hayama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology,Nippon Medical School Chiba Hokusoh Hospital,Chiba,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Nakagawa\u2010Iwashita","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Itokawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisa","family":"Kondo","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Nagao","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Sugihara","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Iwakiri","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Nippon Medical School,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"hep42069-bib-0001-20241104","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2010meta\u2010analytic assessment of prevalence, incidence, and outcomes","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"hep42069-bib-0002-20241104","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","year":"2006","journal-title":"Hepatology"},{"key":"hep42069-bib-0003-20241104","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long\u2010term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"hep42069-bib-0004-20241104","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy\u2010proven NAFLD","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep42069-bib-0005-20241104","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/jgh.14989","article-title":"Long\u2010term outcomes of non\u2010alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population","volume":"35","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"hep42069-bib-0006-20241104","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","year":"2013","journal-title":"Hepatology"},{"key":"hep42069-bib-0007-20241104","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/hep4.1105","article-title":"Progression of liver fibrosis is associated with non\u2010liver\u2010related mortality in patients with nonalcoholic fatty liver disease","volume":"1","year":"2017","journal-title":"Hepatol Commun"},{"key":"hep42069-bib-0008-20241104","article-title":"Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy\u2010proven nonalcoholic fatty liver disease","volume":"11","year":"2021","journal-title":"Sci Rep"},{"key":"hep42069-bib-0009-20241104","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.dld.2017.01.147","article-title":"AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions","volume":"49","year":"2017","journal-title":"Dig Liver Dis"},{"key":"hep42069-bib-0010-20241104","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00535-013-0911-1","article-title":"Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients","volume":"49","year":"2014","journal-title":"J Gastroenterol"},{"key":"hep42069-bib-0011-20241104","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.25772","article-title":"Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis","volume":"56","year":"2012","journal-title":"Hepatology"},{"key":"hep42069-bib-0012-20241104","article-title":"Anti\u2010fibrotic activity of sitagliptin against concanavalin A\u2010induced hepatic fibrosis. Role of Nrf2 activation\/NF\u2010\u03baB inhibition","volume":"100","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"hep42069-bib-0013-20241104","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non\u2010alcoholic steatohepatitis (LEAN): a multicentre, double\u2010blind, randomised, placebo\u2010controlled phase 2 study","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"hep42069-bib-0014-20241104","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep4.1019","article-title":"Effects of a sodium\u2010glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies","volume":"1","year":"2017","journal-title":"Hepatol Commun"},{"key":"hep42069-bib-0015-20241104","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","year":"2020","journal-title":"Dig Dis Sci"},{"key":"hep42069-bib-0016-20241104","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","year":"2022","journal-title":"Hepatol Commun"},{"key":"hep42069-bib-0017-20241104","article-title":"Effect of sodium\u2010glucose cotransporter 2 inhibitor in patients with non\u2010alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score\u2010matched analysis of real\u2010world data","volume":"12","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"hep42069-bib-0018-20241104","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/hepr.12834","article-title":"Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non\u2010alcoholic fatty liver disease and type 2 diabetes mellitus","volume":"47","year":"2017","journal-title":"Hepatol Res"},{"key":"hep42069-bib-0019-20241104","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E\u2010LIFT trial)","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"hep42069-bib-0020-20241104","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hepr.13236","article-title":"Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non\u2010alcoholic fatty liver disease: a prospective, single\u2010arm trial (LEAD trial)","volume":"49","year":"2019","journal-title":"Hepatol Res"},{"key":"hep42069-bib-0021-20241104","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","year":"2006","journal-title":"Hepatology"},{"key":"hep42069-bib-0022-20241104","article-title":"Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population","volume":"12","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"hep42069-bib-0023-20241104","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep42069-bib-0024-20241104","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2017.09.012","article-title":"Association between non\u2010alcoholic fatty liver disease and cancer incidence rate","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep42069-bib-0025-20241104","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2169\/internalmedicine.9853-17","article-title":"The clinical difference in the platelet counts between liver cirrhosis with nonalcoholic fatty liver disease and hepatitis C virus","volume":"57","year":"2018","journal-title":"Intern Med"},{"key":"hep42069-bib-0026-20241104","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1007\/s00535-011-0436-4","article-title":"Platelet count for predicting fibrosis in nonalcoholic fatty liver disease","volume":"46","year":"2011","journal-title":"J Gastroenterol"},{"key":"hep42069-bib-0027-20241104","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/hepr.13688","article-title":"Evidence\u2010based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020","volume":"51","year":"2021","journal-title":"Hepatol Res"},{"key":"hep42069-bib-0028-20241104","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","year":"2020","journal-title":"Gut"},{"key":"hep42069-bib-0029-20241104","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non\u2010alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta\u2010analysis","volume":"71","year":"2022","journal-title":"Gut"},{"key":"hep42069-bib-0030-20241104","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"hep42069-bib-0031-20241104","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cgh.2020.04.067","article-title":"Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta\u2010analysis","volume":"19","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep42069-bib-0032-20241104","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/hep4.1668","article-title":"Sex and menopause modify the effect of single nucleotide polymorphism genotypes on fibrosis in NAFLD","volume":"5","year":"2021","journal-title":"Hepatol Commun"},{"key":"hep42069-bib-0033-20241104","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries","volume":"112","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"hep42069-bib-0034-20241104","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.31317","article-title":"Alanine aminotransferase and gamma\u2010glutamyl transpeptidase predict histologic improvement in pediatric nonalcoholic steatohepatitis","volume":"73","year":"2021","journal-title":"Hepatology"},{"key":"hep42069-bib-0035-20241104","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jhep.2005.06.018","article-title":"Hepatic steatosis and insulin resistance: does etiology make a difference?","volume":"44","year":"2006","journal-title":"J Hepatol"},{"key":"hep42069-bib-0036-20241104","article-title":"Gamma\u2010glutamyl transferase and cardiovascular disease","volume":"4","year":"2016","journal-title":"Ann Transl Med"},{"key":"hep42069-bib-0037-20241104","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep42069-bib-0038-20241104","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/hep4.1611","article-title":"Impact of sodium glucose cotransporter 2 inhibitors on nonalcoholic fatty liver disease complicated by diabetes mellitus","volume":"5","year":"2021","journal-title":"Hepatol Commun"},{"key":"hep42069-bib-0039-20241104","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00535-016-1200-6","article-title":"Ipragliflozin, a sodium\u2010glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka long\u2010Evans Tokushima fatty rats","volume":"51","year":"2016","journal-title":"J Gastroenterol"},{"key":"hep42069-bib-0040-20241104","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"hep42069-bib-0041-20241104","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP\u20104 inhibitor), prevents steatohepatitis in a novel mouse model of non\u2010alcoholic steatohepatitis and diabetes","volume":"8","year":"2016","journal-title":"Diabetol Metab Syndr"},{"key":"hep42069-bib-0042-20241104","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","year":"2020","journal-title":"Nat Commun"},{"key":"hep42069-bib-0043-20241104","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.30252","article-title":"NLR family pyrin domain\u2010containing 3 inflammasome activation in hepatic stellate cells induces liver fibrosis in mice","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"hep42069-bib-0044-20241104","article-title":"Inhibition of sodium glucose cotransporters improves cardiac performance","volume":"20","year":"2019","journal-title":"Int J Mol Sci"},{"key":"hep42069-bib-0045-20241104","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","year":"2019","journal-title":"Diabetologia"},{"key":"hep42069-bib-0046-20241104","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH","volume":"8","year":"2018","journal-title":"Sci Rep"},{"key":"hep42069-bib-0047-20241104","article-title":"The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non\u2010alcoholic steatohepatitis\u2010related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma","volume":"20","year":"2019","journal-title":"Int J Mol Sci"},{"key":"hep42069-bib-0048-20241104","article-title":"Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: multi\u2010omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)","volume":"15","year":"2020","journal-title":"PLoS One"},{"key":"hep42069-bib-0049-20241104","article-title":"Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep42069-bib-0050-20241104","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","year":"2018","journal-title":"Hepatology"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.2069","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.2069","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:00:36Z","timestamp":1730707236000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.2069","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"2022-02-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}